Company intelligence / Profile preview

Sobi

Ownership: Public · SOBI
Employees: ~702
Development stage: Commercial

Overview

Sobi has multiple approved products including Kineret, Elocta (Altuvoct), and Doptelet. In 2024, they received marketing authorization for ALTUVOCT from the European Commission, and their supplemental New Drug Application for avatrombopag (DOPTELET) to treat patients with thrombocytopenia was accepted by the FDA[4].

Therapeutic areas: Metabolic DisordersImmunologyHematologyRare DiseasesNeurology
Modalities: Biologicsprotein biochemistry
Industry: Biotech

Drug pipeline

27 assets

anakinra

Approved

26 more assets in the full pipeline.

Request access →

Partnerships

Boehringer Ingelheim (manufacturing partner for Kineret)Enable Injections (for the enFuse Injector for subcutaneous delivery of Aspaveli)PharmaSwiss (commercial rights in Europe to three products)[6][4][8]

Financials

Market cap: $260.7M
Total revenue: $32.6M

Beyond the preview

Go deeper on Sobi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sobi.

Explore the full profile